Alembic Pharma Reports 15% Jump in Q1 Net Profit, Revenue Grows 10%
Alembic Pharmaceuticals posted robust Q1 FY24 results. Net profit increased by 15% to ₹154.00 crore, while revenue grew 10% to ₹1,711.00 crore year-on-year. EBITDA rose 19% to ₹282.00 crore, with EBITDA margin expanding by 130 bps to 16.50%. Despite positive financials, the company's stock traded flat at ₹968.75, with an 8% year-to-date decline.
26Jul 25
Alembic Pharma Secures USFDA Approval for Carbamazepine Extended Release Tablets
Alembic Pharmaceuticals received final USFDA approval for Carbamazepine extended release tablets in 100mg, 200mg, and 400mg strengths. The drug, equivalent to Novartis' Tegretol-XR, is used as an anti-convulsant and for treating trigeminal neuralgia pain. The estimated market size for these tablets is $71.00 million for the 12 months ending March 2025. This approval brings Alembic's total ANDA approvals to 225, including 202 final and 23 tentative approvals. Despite the news, Alembic's shares closed 1.91% lower at ₹999.00.
13May 25
Alembic Reports Q4 Profit Growth and Announces Dividend
Alembic Pharmaceuticals has released its Q4 financial results, showing significant growth. Net profit increased by 11.8% to ₹238.00 crore, while revenue grew by 23% to ₹603.00 crore. EBITDA rose by 13% to ₹273.00 crore, although the EBITDA margin slightly decreased. The company's board has recommended a dividend of ₹2.40 per equity share.